Novel EGFR Truncations as Biomarker and Target

New truncation mutants of EGFR in primary human tumors and cell line which may be used as a biomarker and a therapeutic target Background: Three new truncation mutants have been discovered in primary human tumors and cell lines. These mutants may possess oncogenic activities and render some tumors resistant to certain inhibitors. These newly discovered mutants may be used as biomarkersfor predicting patients? response to specific targeting agents. Technology Overview: Dr. Edward Chan, Assistant Professor at Stony Brook University discovered three new truncation mutants of EGFR in primary human tumors and cell lines. These mutations may be used as biomarkers for predicting a patients' response to anti-EGFR drugs,molecular diagnostic for micrometastasis/minimal residual disease monitoring or become new therapeutic targets for drug and antibody development. Advantages: New EGFR truncation mutants may be used for predicting patients' responce to EGFR targeting agents. Counld become new therapeutic targets for drug and antibody development. Applications: Biomarker for predicting patients' responce to anti-EGFR drugs. Therapeutic target for drug and antibody development. Intellectual Property Summary: PCT Publication No. WO 2011-140391 Stage of Development: Antibody developed; need clinical validation. Licensing Potential: We seek to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area. Licensing Status: Available for License Additional Information: EGFR768, EGFR471, EGFR660, Truncated EGFR https://stonybrook.technologypublisher.com/files/sites/diagnosis11.jpg
Patent Information:
Technology/Start-up ID: